Valuation: Kinarus Therapeutics Holding AG

Market Cap 4.72M 5.59M 5.1M 4.26M 8.02M 523M 8.33M 56.96M 22.52M 282M 20.98M 20.54M 891M P/E 2022
-0.23x
P/E 2023 -0.01x
Enterprise Value 4.71M 5.58M 5.09M 4.25M 8M 522M 8.32M 56.86M 22.47M 282M 20.94M 20.51M 889M EV / Sales 2022
4,318,722x
EV / Sales 2023 -
Free-Float
-
Yield 2022 *
-
Yield 2023 -
1 day-5.63%
Current month-6.37%
Current year-6.37%
3 years 0.9
Extreme 0.895999
33.15
5 years 0.9
Extreme 0.895999
230.27
10 years 0.9
Extreme 0.895999
230.27

Financials

2022 2023
Net sales 3.34 3.96 3.61 3.01 5.67 369.69 5.89 40.29 15.93 199.55 14.84 14.53 630.11 -
Net income -34.73M -41.19M -37.56M -31.34M -59.03M -3.85B -61.36M -419M -166M -2.08B -155M -151M -6.56B -49.38M -58.56M -53.41M -44.56M -83.93M -5.47B -87.24M -596M -236M -2.95B -220M -215M -9.33B
Net Debt 1.66M 1.97M 1.79M 1.5M 2.82M 184M 2.93M 20.02M 7.92M 99.17M 7.38M 7.22M 313M -9K -10.67K -9.73K -8.12K -15.3K -997K -15.9K -109K -42.97K -538K -40.04K -39.2K -1.7M
Projected Income Statement - Annual - Kinarus Therapeutics Holding AG
Logo Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
Employees
-
Sector
-
Date Price Change
18/11/26 CHF 15.10 -5.63%
17/11/26 CHF 16.00 +6.31%
16/11/26 CHF 15.05 -5.94%
13/11/26 CHF 16.00 -4.76%
12/11/26 CHF 16.80 -5.88%
  1. Stock Market
  2. Stocks
  3. CURE Stock